Wilson Disease epidemiology report 2030 gives a thorough understanding of the Wilson Disease by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Wilson Disease Epidemiology Insight

DelveInsight’s ‘Wilson’s Disease (WD) – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of and historical and forecasted epidemiology of Wilson’s disease (WD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<h2>Geographies Covered</h2><ul><li>The United States</li><li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li><li>Japan</li></ul>Study Period: 2018–2030<h2>Wilson’s disease (WD) Disease Understanding</h2>Wilson’s disease (WD) is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly the liver, brain, and corneas of the eyes. The disease is progressive and, if left untreated, it may cause liver (hepatic) disease, central nervous system dysfunction, and death. Early diagnosis and treatment may prevent serious long-term disability and life-threatening complications. WD is a rare genetic disorder beginning with liver dysfunction where damage begins by 6 years of age, but it is usually present clinically in the teenage years or early 20s. Common signs of associated liver disease include a yellow discoloration (jaundice) of the skin, mucous membranes and the membranes (sclera) that line the eye, swelling (edema) of the legs and abdomen (ascites) due to abnormal retention of fluid, presence of abnormal blood vessels in the esophagus that may bleed (esophageal varices), a tendency for bruising and prolonged bleeding, and excessive tiredness (fatigue). Some individuals with Wilson’s disease may have only liver function abnormalities and may show no other symptoms until many years later. Mutations in the ATP7B gene are known to cause WD. This gene encodes a protein that plays a vital role in transporting copper from the liver to the rest of the body. It also helps remove excess copper from the body. Mutations in the ATP7B gene prevent this protein from working properly, leading to an accumulation of copper in the body. Because high copper levels are toxic, this build-up can damage tissues and organs and cause the many signs and symptoms of WD. As prompt diagnosis is crucial to initiate treatment hopefully in the early, asymptomatic stage of the disease and not when liver decompensation or advanced neurological irreversible damage has already ensued, family screening is warranted. In this scenario, the best approach is to complete copper studies in first- and second-degree relatives of the index case.&nbsp;<h2>Wilson’s disease (WD) Epidemiology</h2>The Wilson’s disease (WD) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key FindingsThe disease epidemiology covered in the report provides historical as well as forecasted WD epidemiology segmented as the total prevalent cases of Wilson’s disease (WD), diagnosed prevalent cases of Wilson’s disease (WD), prevalent cases of Wilson’s disease (WD) by clinical manifestation. The report includes the prevalence scenario of Wilson’s disease (WD) symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.<h2>Country-wise, Wilson’s disease (WD) Epidemiology</h2>The epidemiology segment also provides Wilson’s disease (WD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The total prevalent population of Wilson’s disease (WD) in the 7MM countries was estimated to be 35,509 in 2020, and it is expected to increase at a CAGR of 0.07% during the study period, i.e., 2018–2030.<ul><li>As per the estimates, Japan has the highest prevalent population of Wilson’s disease (WD) in the 7MM.</li><li>Among the EU5 countries, Germany had the highest prevalent population of Wilson’s disease (WD). On the other hand, Spain had the lowest number, 797 cases in 2020.</li></ul><h2>Scope of the Report</h2><ul><li>Wilson’s disease (WD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns</li><li>Wilson’s disease (WD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Wilson’s disease (WD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)</li><li>The report provides insight into the historical and forecasted patient pool of Wilson’s disease (WD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan</li><li>The report helps recognize the growth opportunities in the 7MM concerning the patient population</li><li>The report assesses the disease risk and burden and highlights the unmet needs of Wilson’s disease (WD).</li><li>The report provides the segmentation of Wilson’s disease (WD) epidemiology by prevalent Cases of Wilson’s disease (WD) in the 7MM</li><li>The report provides the segmentation of Wilson’s disease (WD) epidemiology by diagnosed prevalent cases of Wilson’s disease (WD) in 7MM</li><li>The report provides the segmentation of Wilson’s disease (WD) epidemiology by prevalent cases of Wilson’s disease (WD) by clinical manifestation in 7MM</li></ul><h2>Report Highlights</h2><ul><li>10-year Forecast of Wilson’s disease (WD) epidemiology</li><li>7MM Coverage</li><li>Total Prevalent Cases of Wilson’s disease (WD)</li><li>Diagnosed prevalent cases of Wilson’s disease (WD)</li><li>Prevalent cases of Wilson’s disease (WD) by clinical manifestation</li></ul><h2>KOL Views</h2>We interview KOLs, and SME’s Opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.<h2>Key Questions Answered</h2><ul><li>What will be the growth opportunities in the 7MM concerning the patient population about Wilson’s disease (WD)?</li><li>What are the key findings of Wilson’s disease (WD) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2030)?</li><li>What would be the total number of patients with Wilson’s disease (WD) across the 7MM during the forecast period (2021–2030)?</li><li>Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2030)?</li><li>At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2030)?</li><li>What are the currently available treatments for Wilson’s disease (WD)?</li></ul><h2>Reasons to buy</h2>The Wilson’s disease (WD) Epidemiology report will allow the user to:<ul><li>Develop business strategies by understanding the trends shaping and driving the global Wilson’s disease (WD) market</li><li>Quantify patient populations in the global Wilson’s disease (WD) market to improve product design, pricing, and launch plans</li><li>Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Wilson’s disease (WD) therapeutics in each of the markets covered</li><li>Understand the magnitude of Wilson’s disease (WD) population by its Prevalent cases</li><li>Understand the magnitude of Wilson’s disease (WD) population by its Types-specific cases</li><li>The Wilson’s disease (WD) epidemiology report and model was written and developed by Masters and PhD level epidemiologists</li><li>The Wilson’s disease (WD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources</li></ul><h2>Key Assessments</h2><ul><li>Patient Segmentation</li><li>Disease Risk and Burden</li><li>Risk of disease by the segmentation</li><li>Factors driving growth in a specific patient population</li></ul>

1. Key Insights2. Report Introduction3. Wilson’s disease Epidemiology Overview at a Glance3.1. Patient Share (%) Distribution of Wilson’s disease in 20183.2. Patient Share (%) Distribution of Wilson’s disease in 20304. Executive Summary of Wilson’s disease5. Disease Background and Overview5.1. Introduction5.2. Symptoms5.3. Etiology5.4. Clinical Manifestation5.5. Copper Metabolism5.6. Pathogenesis5.7. Diagnosis6. Epidemiology and Patient Population6.1. Key Findings6.2. 7MM Total Prevalent Patient Population of Wilson’s disease6.3. Epidemiology of Wilson’s disease6.4. The United States6.4.1. Prevalent Cases of Wilson’s disease in the United States6.4.2. Diagnosed Prevalent Cases of Wilson’s disease in the United States6.4.3. Prevalent cases of Wilson’s disease based on Clinical Manifestation in the US6.5. EU56.5.1. Germany6.5.2. France6.5.3. Italy6.5.4. Spain6.5.5. United Kingdom6.6. Japan6.6.1. Prevalent Cases of Wilson’s disease in Japan6.6.2. Diagnosed Prevalent Cases of Wilson’s disease in Japan6.6.3. Prevalent cases of Wilson’s disease based on Clinical Manifestation in Japan7. Treatment of Wilson’s disease8. Organizations contributing towards Wilson’s disease9. Patient Journey10. Case Reports11. KOL Views12. Appendix12.1. Bibliography12.2. Report Methodology13. DelveInsight Capabilities14. Disclaimer15. About DelveInsight

Wilson Disease - Epidemiology Forecast to 2030

DelveInsight's Wilson Disease - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical....